Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25
years now. The first clinical observations in patients with refractory Crohn's disease rapidly …

Several anti-tumour necrosis factor [TNF] blocking strategies have been evaluated in
patients with Crohn's disease. Compounds that have been tested included the full …

The current treatment of Crohn's disease is limited by a lack of long-term efficacy of
corticosteroid therapy and the associated side effects. Biological treatment strategies aimed …

Infliximab, the chimeric monoclonal immunoglobulin (Ig) G1 antibody to tumor necrosis
factor (TNF) has changed our therapy of Crohn's disease. Infliximab is indicated in refractory …

Background Anti‐TNF agents are now widely used in Crohn's disease (CD), and in
ulcerative colitis (UC). Aim To review the safety profile of anti‐TNF agents in all patients …

Tumor necrosis factor‐α (TNFα), a proinflammatory cytokine, plays an important role in the
pathogenesis of inflammatory bowel disease (IBD). Biotechnology agents including a …

Crohn's disease and ulcerative colitis are two idiopathic inflammatory disorders of the GI
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …

Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …

Tumour necrosis factor (TNF) plays an important role in mediating the inflammation of
inflammatory bowel disease, in particular, Crohn's disease. Strategies aimed at reducing …

Aliment Pharmacol Ther 2011; 33: 857–869 Summary Background Crohn's disease is a
progressive condition, with most patients developing a penetrating or stricturing …